BBB National Programs Newsroom

NARB Recommends Benefiber Discontinue “100% Natural” and “Clinically Proven” Claims, But Finds “Helps You Feel Fuller Longer” Claim Supported

For Immediate Release
Contact: Abby Hills, Director of Communications, BBB National Programs

703-247-9330 / press@bbbnp.org

New York, NY – October 22, 2020 – A panel of the National Advertising Review Board (NARB), a division of BBB National Programs, recommended that GlaxoSmithKline Consumer Healthcare, LLC (GSK) discontinue “100% natural” and “clinically proven to curb cravings” claims for Benefiber Original and Benefiber Healthy Shape (Benefiber). However, the panel determined that GSK provided a reasonable basis for its claim that Benefiber “helps you feel fuller longer.” 

The advertising at issue had been challenged by The Procter & Gamble Company (P&G) before the National Advertising Division (NAD). Following NAD’s decision (Case No. 6366), GSK appealed NAD’s findings regarding these claims.

The sole ingredient in Benefiber is wheat dextrin. The panel concluded that, if the process by which wheat dextrin is manufactured were explained to consumers, they would likely not view the product as “100% natural.” Therefore, the panel determined that GSK’s “100% natural” claim is not supported and recommended that it be discontinued. The panel noted, however, that its conclusion regarding the “100% natural” claim “should not be interpreted as prejudging a more limited or qualified use of ‘natural’ that might be supported by the evidence.”

With regard to GSK’s satiety claim that Benefiber is “clinically proven to curb cravings,” the NARB panel noted that a “clinically proven” claim for a product offered to provide health benefits is a strong claim that should be supported by robust evidence from clinical studies. The panel concluded that GSK’s “clinically proven” claim is unsupported and should be withdrawn because each of the seven clinical studies relied on by GSK were subject to valid criticism as to whether they constituted a “good fit” for the claim.

However, the panel determined that GSK’s second satiety claim, “help you feel fuller longer,” is supported. The panel noted that the claim is qualified by use of the word “helps,” and concluded that the results of the seven clinical studies relied on by the advertiser, taken as a whole, are supportive of this more limited claim.

GSK stated that it will comply with NARB’s decision. GSK further stated that while it “respectfully disagrees with NARB’s determination that the ‘100% Natural’ claim is not substantiated . . . GSK appreciates the NARB’s recognition that GSK can make a more limited or qualified ‘natural’ claim that is supported by the evidence.”

###

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.

About the National Advertising Review Board (NARB): The National Advertising Review Board (NARB) is the appellate body for BBB National Programs’ advertising self-regulatory programs. NARB’s panel members include 87 distinguished volunteer professionals from the national advertising industry, agencies, and public members, such as academics and former members of the public sector. NARB serves as a layer of independent industry peer review that helps engender trust and compliance in NAD, CARU, and DSSRC matters. 

NARB Recommends Benefiber Discontinue “100% Natural” and “Clinically Proven” Claims, But Finds “Helps You Feel Fuller Longer” Claim Supported

For Immediate Release
Contact: Abby Hills, Director of Communications, BBB National Programs

703-247-9330 / press@bbbnp.org

New York, NY – October 22, 2020 – A panel of the National Advertising Review Board (NARB), a division of BBB National Programs, recommended that GlaxoSmithKline Consumer Healthcare, LLC (GSK) discontinue “100% natural” and “clinically proven to curb cravings” claims for Benefiber Original and Benefiber Healthy Shape (Benefiber). However, the panel determined that GSK provided a reasonable basis for its claim that Benefiber “helps you feel fuller longer.” 

The advertising at issue had been challenged by The Procter & Gamble Company (P&G) before the National Advertising Division (NAD). Following NAD’s decision (Case No. 6366), GSK appealed NAD’s findings regarding these claims.

The sole ingredient in Benefiber is wheat dextrin. The panel concluded that, if the process by which wheat dextrin is manufactured were explained to consumers, they would likely not view the product as “100% natural.” Therefore, the panel determined that GSK’s “100% natural” claim is not supported and recommended that it be discontinued. The panel noted, however, that its conclusion regarding the “100% natural” claim “should not be interpreted as prejudging a more limited or qualified use of ‘natural’ that might be supported by the evidence.”

With regard to GSK’s satiety claim that Benefiber is “clinically proven to curb cravings,” the NARB panel noted that a “clinically proven” claim for a product offered to provide health benefits is a strong claim that should be supported by robust evidence from clinical studies. The panel concluded that GSK’s “clinically proven” claim is unsupported and should be withdrawn because each of the seven clinical studies relied on by GSK were subject to valid criticism as to whether they constituted a “good fit” for the claim.

However, the panel determined that GSK’s second satiety claim, “help you feel fuller longer,” is supported. The panel noted that the claim is qualified by use of the word “helps,” and concluded that the results of the seven clinical studies relied on by the advertiser, taken as a whole, are supportive of this more limited claim.

GSK stated that it will comply with NARB’s decision. GSK further stated that while it “respectfully disagrees with NARB’s determination that the ‘100% Natural’ claim is not substantiated . . . GSK appreciates the NARB’s recognition that GSK can make a more limited or qualified ‘natural’ claim that is supported by the evidence.”

###

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.

About the National Advertising Review Board (NARB): The National Advertising Review Board (NARB) is the appellate body for BBB National Programs’ advertising self-regulatory programs. NARB’s panel members include 87 distinguished volunteer professionals from the national advertising industry, agencies, and public members, such as academics and former members of the public sector. NARB serves as a layer of independent industry peer review that helps engender trust and compliance in NAD, CARU, and DSSRC matters. 

Blog

Navigating In-App Advertising in Children’s Apps

While the FCC regulates children’s cable television and allows for only 10.5-12 minutes of advertising to be shown per hour, there is no comparable guidance to regulate the volume or frequency of ads in digital advertising. Most mobile device users have grown accustomed to dealing with the ubiquitous presence of ads in apps. However, there are a few ad practices that can become problematic when used in children’s apps. Read on to see what our experts had to say.
Read more
Blog

CARU's Tips for Parents: Safe and Efficient Holiday Shopping

2020 has been a year unlike any other. In a time of great uncertainty, facing the holidays can feel be daunting. When it comes to holiday shopping, it is safe to say that many of us will be primarily shopping online this year. To help ensure your online holiday shopping experience is safe and efficient this holiday season, the Children’s Advertising Review Unit (CARU) team has put together some tips and red flags to consider when making those all-important gift selections.
Read more
Blog

After Seven Months, the Verdict is in: Fast-Track SWIFT is Fast and Fair

The National Advertising Division (NAD) Fast-Track SWIFT advertising challenge process launched seven months ago as a faster way to resolve single-issue cases. The process has kept its promise of fast and fair decisions. This blog covers lessons learned and best practices gathered by the NAD team since the launch of SWIFT.
Read more
Blog

Monetization: The Privacy Risks and Rewards of In-App Purchases and IBA

Every day, teens download apps for free on the Google Play and Apple App Stores and, in doing so, participate in a hidden advertising ecosystem that collects data from them. In-app purchase options and behavioral advertising further complicate things. Though these monetization models have caused the mobile app economy to flourish, they sometimes come at the cost of user privacy.
Read more

NARB Recommends Benefiber Discontinue “100% Natural” and “Clinically Proven” Claims, But Finds “Helps You Feel Fuller Longer” Claim Supported

For Immediate Release
Contact: Abby Hills, Director of Communications, BBB National Programs

703-247-9330 / press@bbbnp.org

New York, NY – October 22, 2020 – A panel of the National Advertising Review Board (NARB), a division of BBB National Programs, recommended that GlaxoSmithKline Consumer Healthcare, LLC (GSK) discontinue “100% natural” and “clinically proven to curb cravings” claims for Benefiber Original and Benefiber Healthy Shape (Benefiber). However, the panel determined that GSK provided a reasonable basis for its claim that Benefiber “helps you feel fuller longer.” 

The advertising at issue had been challenged by The Procter & Gamble Company (P&G) before the National Advertising Division (NAD). Following NAD’s decision (Case No. 6366), GSK appealed NAD’s findings regarding these claims.

The sole ingredient in Benefiber is wheat dextrin. The panel concluded that, if the process by which wheat dextrin is manufactured were explained to consumers, they would likely not view the product as “100% natural.” Therefore, the panel determined that GSK’s “100% natural” claim is not supported and recommended that it be discontinued. The panel noted, however, that its conclusion regarding the “100% natural” claim “should not be interpreted as prejudging a more limited or qualified use of ‘natural’ that might be supported by the evidence.”

With regard to GSK’s satiety claim that Benefiber is “clinically proven to curb cravings,” the NARB panel noted that a “clinically proven” claim for a product offered to provide health benefits is a strong claim that should be supported by robust evidence from clinical studies. The panel concluded that GSK’s “clinically proven” claim is unsupported and should be withdrawn because each of the seven clinical studies relied on by GSK were subject to valid criticism as to whether they constituted a “good fit” for the claim.

However, the panel determined that GSK’s second satiety claim, “help you feel fuller longer,” is supported. The panel noted that the claim is qualified by use of the word “helps,” and concluded that the results of the seven clinical studies relied on by the advertiser, taken as a whole, are supportive of this more limited claim.

GSK stated that it will comply with NARB’s decision. GSK further stated that while it “respectfully disagrees with NARB’s determination that the ‘100% Natural’ claim is not substantiated . . . GSK appreciates the NARB’s recognition that GSK can make a more limited or qualified ‘natural’ claim that is supported by the evidence.”

###

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.

About the National Advertising Review Board (NARB): The National Advertising Review Board (NARB) is the appellate body for BBB National Programs’ advertising self-regulatory programs. NARB’s panel members include 87 distinguished volunteer professionals from the national advertising industry, agencies, and public members, such as academics and former members of the public sector. NARB serves as a layer of independent industry peer review that helps engender trust and compliance in NAD, CARU, and DSSRC matters. 

Media Inquiry

*Required fields